Envista Holdings Co. (NYSE:NVST) Given Average Rating of “Hold” by Analysts

Envista Holdings Co. (NYSE:NVST) has been assigned a consensus recommendation of “Hold” from the fourteen research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $20.08.

A number of equities analysts recently commented on the company. Morgan Stanley set a $16.00 price target on Envista in a report on Tuesday, April 15th. New Street Research set a $19.00 target price on Envista in a research note on Thursday, March 6th. UBS Group reduced their price objective on shares of Envista from $21.00 to $18.00 and set a “neutral” rating for the company in a research report on Monday. Wells Fargo & Company set a $19.00 price objective on shares of Envista in a research report on Saturday, March 8th. Finally, Jefferies Financial Group lifted their target price on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd.

Institutional Investors Weigh In On Envista

Several institutional investors and hedge funds have recently bought and sold shares of NVST. Franklin Resources Inc. raised its position in shares of Envista by 72.6% in the 4th quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock valued at $132,223,000 after buying an additional 2,882,844 shares in the last quarter. Brickwood Asset Management LLP bought a new stake in Envista during the fourth quarter worth $40,037,000. Norges Bank acquired a new stake in shares of Envista in the 4th quarter valued at $38,052,000. Pzena Investment Management LLC increased its stake in shares of Envista by 160.7% in the 1st quarter. Pzena Investment Management LLC now owns 2,294,257 shares of the company’s stock valued at $39,599,000 after purchasing an additional 1,414,080 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Envista by 19.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company’s stock worth $130,440,000 after buying an additional 1,089,923 shares in the last quarter.

Envista Stock Up 5.5 %

NYSE:NVST opened at $17.77 on Friday. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of -2.74, a price-to-earnings-growth ratio of 1.27 and a beta of 0.97. Envista has a twelve month low of $14.22 and a twelve month high of $23.00. The stock’s 50 day moving average price is $16.50 and its two-hundred day moving average price is $19.00. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.04. The firm had revenue of $616.90 million for the quarter, compared to analyst estimates of $608.17 million. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.26 earnings per share. Equities research analysts expect that Envista will post 1 earnings per share for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.